Dynamics of AMR Spread, Persistence and Evolution Between Humans, Animals and Their Environment

NCT ID: NCT06262009

Last Updated: 2024-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

525 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-30

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Humans in contact with animals such as dog owners, may be at risk of antimicrobial resistance (AMR) acquisition. This is the central issue to be investigated in DYASPEO

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Antimicrobial resistance (AMR) is a global and multifaceted public health problem. Advanced knowledge on AMR has demonstrated that it not only affects humans but is also widely distributed across animals and the environment. A major cause of the AMR burden refers to the capability of AMR to transmit within and between individuals, including between humans and animals. Leading examples of internationally distributed AMR bacteria are Enterobacterial disseminating resistances to extended-spectrum cephalosporins (ESC-E) and carbapenems (CP-E). Yet, the magnitude and pathways of their cross-sectorial transfers are poorly understood.

There is a great concern that humans in contact with animals be at risk of ESC-E/CP-E acquisition. Whereas an increase in ESC-E carriage in farmers in contact with their food-producing animals was reported, AMR transmission to humans through direct contacts with companion animals has been much less studied. Owing the close relationships between pets and owners, and the fact that 50% of households host a dog or a cat in France, the hypothesis of pet ownership being a risk for humans to acquire ESC-E/CP-E appears strongly relevant. The DYASPEO project will investigate this question through a combination of several approaches from field to laboratory studies, and including epidemiology, ecology, molecular and population genomics, studies on intestinal microbiota, modelling and social sciences.

We hypothesize that the interface between humans and companion animals plays a significant role in the transfer of ESC-E/CP-E. This hypothesis is corroborated (i) by recent data in France showing that antibiotic exposure of companion animals is still increasing contrary to all other animal host (e.g. food-producing animals) and (ii) by a recent study from the consortium demonstrating a high AMR prevalence in dogs getting back home after hospitalization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antibiotic Resistant Strain Transmission, Close-Contact

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

household

House Members (adults and minors) from 175 households owning a dog

human faecal collection

Intervention Type OTHER

collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90

ancillary study

Intervention Type OTHER

interviews and/or ethnographic observations for 50 volunteers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

human faecal collection

collecting stools 6 times over a 90 days period and complete a questionnaire at the same times: D1, D7, D15, D30, D60 and D90

Intervention Type OTHER

ancillary study

interviews and/or ethnographic observations for 50 volunteers

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult or child planning to live in the same household as his/her dog during the three months following inclusion.
* Planning to live in the same habitat in the next three months following inclusion (except for holidays).
* Written consent of all adults and of at least one of the two parents for minors under parental authority. A different information note will be elaborated for each age category (6-10 yr-old, 10-15 yr-old and 16-18 yr-old).
* Owning a dog recorded for a surgery at the National Veterinary School

Exclusion Criteria

* Lack of signed informed consent
* Subject in alternating custody
* Subject under legal protection (guardianship)
* Subject deprived of liberty under judicial constraint
* Subject undergoing psychiatric care
* Lack of affiliation to a social security scheme
* Volunteers who do not speak/write French
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Yves Madec, PHD

Role: PRINCIPAL_INVESTIGATOR

ANSES

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the National Veterinary School Alfort

Maisons-Alfort, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jean-Yves Madec, PHD

Role: CONTACT

06 85 08 93 30 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jean-Yves Madec, PHD

Role: primary

06 85 08 93 30 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-A02282-43

Identifier Type: OTHER

Identifier Source: secondary_id

APHP220101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.